William worked for five years at ExonHit Therapeutics as Senior Director of Business Development. During this time, he negotiated multiple extensions to ExonHit Therapeutics’ strategic partnership with Allergan, secured it’s participation in PharmaCog (the European Innovative Medicines Initiative consortium on Alzheimer’s disease) and in-licensed a breast cancer diagnostic discovered by Gustave Roussy Institute.
Prior to joining ExonHit Therapeutics in 2006 and since 2003, William served as a Business Development Director of Roche Pharmaceuticals in the US. During his tenure, he was responsible for out-licensing and divestiture of Roche-developed assets. He led the Roche strategic alliance teams which established the alliances with Syrrx and Amira. From 2000 to 2003, he held various positions at Roche Pharmaceuticals headquarters in Switzerland, including business development responsibilities for CNS and metabolic diseases. He received an MBA from INSEAD and an engineering degree from HEI (Lille, France).
“I am very excited about joining Hybrigenics and look forward to helping the company establish strong partnerships to develop breakthrough therapeutics to treat cancers and other diseases,” said William Vickery, Hybrigenics’ new Head of Corporate and Business Development.
“The addition of William Vickery to our management line-up is key to implementing our top priority strategy which is now focused on partnering inecalcitol for further clinical co-development in prostate cancer. His experience and track record both in pharma and biotech organizations will be extremely valuable,” said Remi Delansorne, Hybrigenics’ CEO.
About Hybrigenics
Hybrigenics SA (http://www.hybrigenics.com) is a bio-pharmaceutical group listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics’ development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis' Taxotere(R), which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics’ research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.
Hybrigenics Services SAS is a fully-owned subsidiary of Hybrigenics SA, and the market leader in Yeast-Two Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life science, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.
HYBRIGENICS is listed on the Alternext by NYSE Euronext
ISIN: FR0004153930
Ticker: ALHYG
Lynne Chapman
ANDREW LLOYD & ASSOCIATES
http://www.ala.com
lynne@ala.com
Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND Tel: +44 1273 675100 Fax: +44 1273 675400
55 rue Boissonade 75014 Paris FRANCE Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01
INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION
